Table 1.

Sample tables automatically generated for surveillance of adverse events following administration of influenza vaccines in VAERS.

(a) Total number of reports of inactivated and live influenza vaccines during the 2014-2015 and 2013-2104 influenza seasons as of 3/27/2015
ALL REPORTS Received Following 2014-15 Seasonal Influenza Vaccines Compared to 2013-14 Seasonal Influenza Vaccines
Initial domestic reports only, VAERS reports as of 03/27/2015a
Influenza vaccine received	Total reports N	Seriousb Fatal N(%)	Seriousb Non-Fatal N(%)	Non-Serious Reports N(%)	Age in years Median (Range)	Male N(%)	Onset interval in daysc Median (Range)
Seasonal total (2014–2015)	8,497	37 (0.4)	435 (5.1)	8,025 (94.4)	51 (0,99)	2,494 (29.4)	0 (0,162)
Seasonal Inactivated	8,028	33 (0.4)	408 (5.1)	7,587 (94.5)	53 (0,99)	2.276 (28.4)	0 (0,162)
Seasonal Live, attenuated	469	4 (0.9)	27 (5.8)	438 (93.4)	10 (0.81)	218 (46.5)	1 (0,36)
Seasonal total (2013-2014)	8,570	29 (0.3)	477 (5 6)	8,064 (94.1)	48 (0,102)	2.555 (29.8)	0 (0,153)
Seasonal Inactivated	7.915	28 (0.4)	443 (5.6)	7,444 (94.0)	51 (0,102)	2,254 (28.5)	0 (0,153)
Seasonal Live, attenuated	655	1 (0.2)	34 (5.2)	620 (94.7)	11 (0,76)	301 (46.0)	0 (0,107)
(b) Reports of newly licensed influenza vaccines by severity and pre-specified conditions during the 2014-2015 influenza season
Reports of NEWLY LICENSED 2014-15 Influenza Vaccines by Severity and Pre-specified Outcomes
Initial domestic reports only, VAERS reports as of 03/27/2015a
Vaccines	All reports N	Seriousb Fatal N(%)	Seriousb Non-Fatal N(%)	GBS N(%)	Anaphylaxis N(%)
IIV4	1,218	1 (0.6)	71 (5.8)	14 (1.1)	8 (0.7)
LAIV4	469	4 (0.9)	27 (5.8)	3 (0.6)	2 (0.4)
RIV3	15				1 (6.7)
ccIV3	222	1 (0.5)	8 (3.6)	4 (1.8)	1 (0.5)

IIV4: Quadrivalent inactivated influenza vaccine; LAIV4: quadrivalent live attenuated influenza vaccine; ccIV3: Flucelvax; RIV3: FluBlok